Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Fisetin, a naturally occurring senolytic compound, reversed vascular dysfunction and aortic stiffening induced by doxorubicin in mice by suppressing senescent cells and their inflammatory secretions, restoring nitric oxide availability. This demonstrates a pharmacological pathway to counter drug-induced premature vascular aging.
Low-dose rapamycin protects DNA in aging immune cells by reducing damage-induced cell death and senescence markers, suggesting mTOR inhibition preserves immune resilience through direct genoprotection rather than broad immunosuppression. This mechanistic clarity offers a more tractable regulatory and therapeutic pathway than the traditional anti-aging framing.
Niagen Bioscience secured a US patent protecting intravenous and injectable formulations of nicotinamide riboside (NR), a NAD+ precursor molecule that declines with age and cellular stress. The patent extends protection through 2044 and positions the company to dominate clinical delivery of NAD+ boosters, a market rapidly expanding across wellness clinics.
Fisetin, a plant-derived senolytic, reverses age-related endothelial dysfunction in aging mice by eliminating senescent endothelial cells and reducing the SASP factor CXCL12, which drives vascular dysfunction through oxidative stress and impaired nitric oxide production. This identifies a mechanistic pathway linking cellular senescence to cardiovascular aging and demonstrates functional recovery through targeted senolytic intervention.
A randomized, placebo-controlled trial in sedentary adults aged 65-85 found that weekly rapamycin (6 mg) blunted functional gains from a 13-week exercise program, with the placebo group showing greater improvements in chair-stand performance and related measures. The drug's 62-hour half-life likely prevented adequate recovery of mTORC1 signaling between training sessions, creating a pharmacokinetic conflict with exercise adaptation.
A mitochondrial protonophore (TLC-6740) combined with tirzepatide produced an additional 4.5% weight loss over tirzepatide alone in a 24-week Phase 2a trial, with concurrent improvements in insulin sensitivity, hepatic function, and body composition. The mechanism leverages cellular energy expenditure to enhance metabolic control, relevant to understanding how pharmacological interventions can address obesity-related metabolic dysfunction at multiple tissue levels.
A pilot study tracking epigenetic aging markers in patients receiving semaglutide for metabolic liver disease found that GLP-1 receptor agonists may slow biological aging rates independent of weight loss alone. The finding suggests semaglutide's effects extend beyond glycemic control to influence aging-related cellular mechanisms, with implications for understanding how pharmacological interventions affect the aging process itself.
The FDA approved a higher-dose semaglutide formulation (Wegovy HD, 7.2 mg) in 54 days under expedited review, signaling that metabolic disease now carries national priority status alongside traditionally serious conditions. The approval demonstrates additional weight loss benefit with a comparable safety profile to lower doses, though gastrointestinal side effects remain common and new sensory symptoms warrant ongoing monitoring.
Antag is testing AT7687, a GIP receptor antagonist, combined with semaglutide in a Phase 2a trial for weight loss and type 2 diabetes management. The 13-week study enrolls 150 participants to evaluate body weight reduction and glycemic control as primary and secondary endpoints, with results expected in H1 2027.
Elysium Health has launched Creatine+, a three-ingredient formulation combining creatine monohydrate, HMB, and pomegranate polyphenols designed to support muscle strength, recovery, and mitochondrial function across the lifespan. As longevity science shifts focus from lifespan extension to preservation of physical function, muscle health has emerged as a critical determinant of healthy aging, reframing creatine from a sports supplement to a foundational longevity tool.
NAD⁺ decline during menopause impairs mitochondrial function and energy production across multiple systems simultaneously. NMN, as a direct NAD⁺ precursor, bypasses rate-limiting steps in NAD⁺ biosynthesis to support cellular energy restoration and repair capacity.
A peer-reviewed analysis of nicotinamide riboside (NR) supplementation found that 1,000 mg daily for five months was associated with approximately 2.5 years of reduction in muscle epigenetic age acceleration, measured across multiple biological clocks. The findings suggest NAD+ restoration may influence molecular aging pathways in skeletal muscle beyond simple energy production, though researchers emphasize additional work is needed to establish causation.
Aging amplifies the liver's inflammatory and metabolic response to high-fat diet, increasing hepatic steatosis and transcriptional dysregulation. Rapamycin treatment reversed most diet-driven gene expression changes in older mice, reducing steatosis, body weight gain, and markers associated with liver disease progression.
Researchers demonstrated that combining NMN supplementation with apigenin—which inhibits NAD+ breakdown—restores muscle function and bone structure in aged mice. This dual approach addresses both supply and preservation of NAD+, a critical coenzyme in cellular energy metabolism and stress resistance.
MS 001, an oral purine nucleoside phosphorylase inhibitor, enhanced GLP-1 receptor agonist efficacy in preclinical models by producing greater weight loss while preserving muscle mass and reducing weight regain after drug discontinuation. The mechanism appears to involve activation of thermogenic pathways in adipose tissue, suggesting a complementary approach to current weight management strategies.
Metashape Pharma's preclinical data demonstrate that MS 001, a purine nucleoside phosphorylase inhibitor, combined with semaglutide produces selective fat loss while preserving muscle mass in diet-induced obese mice through increased thermogenesis. This addresses a critical limitation of GLP-1 monotherapy—undesired muscle loss during weight reduction—with direct implications for preserving metabolic capacity and physical function during longevity-focused weight management.
A 16-week trial in 103 older adults (mean age 68) demonstrates that creatine supplementation amplifies the benefits of high-load, velocity-intentional resistance training—particularly in markers of neuroplasticity, oxidative stress, and inflammation—though cognitive gains showed no synergistic effect. This addresses a significant gap in gerontological research, as creatine has been understudied in aging populations where its ATP-enhancing properties could meaningfully support the preservation of fast-twitch muscle function.
A pooled analysis of clinical trials and laboratory work found that five months of nicotinamide riboside supplementation correlated with approximately 2.5 years of reduction in muscle epigenetic age, measured by multiple clock algorithms. The finding suggests NAD+ precursor supplementation may influence age-related molecular signatures in skeletal muscle, though the company acknowledges results are preliminary and largely correlational.
A randomized controlled trial combining rapamycin and exercise showed no significant improvement in physical function or body composition compared to exercise alone, challenging the hypothesis that mTOR inhibition enhances the adaptive response to resistance training in older adults.
Insilico Medicine's AI-designed drug ISM0676 achieved up to 31.3% weight loss in preclinical studies when combined with semaglutide, with a mechanistic approach targeting metabolic regulation rather than appetite suppression alone. The compound preserved lean muscle mass during weight loss and showed favorable safety and pharmacokinetic properties, suggesting potential advantages over current GLP-1 therapies for sustained metabolic health.
OrsoBio's mitochondrial protonophore TLC-6740 produced an additional 4.5% weight loss when combined with tirzepatide, alongside improvements in insulin sensitivity and liver health, while demonstrating safety comparable to GLP-1 monotherapy. The approach targets energy expenditure rather than appetite suppression, representing a shift toward dual-pathway obesity treatment and metabolic resilience optimization.
NAD+ awareness has transitioned from niche biohacker circles to mainstream consumer interest, with companies like Restore positioning supplementation as a long-term cellular maintenance strategy rather than a rapid intervention. The shift reflects a maturing longevity market moving away from anti-aging hype toward evidence-informed consistency.
GLP-1 receptor agonists produce weight loss with lean body mass reduction comparable to caloric restriction alone, with minimal impact on muscle function. The reduction in lean body mass appears driven largely by liver mass loss rather than skeletal muscle depletion.
Dehydroepiandrosterone sulfate (DHEAS) levels correlate with subjective health perception in a longitudinal population study, suggesting this adrenal steroid may serve as a physiological marker for how individuals experience their own health status. The finding bridges objective biochemistry with subjective well-being, relevant to understanding which biomarkers meaningfully predict health experience across the lifespan.
